{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457121095
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[alpha-v beta-3]] integrin
<!-- Clinical data -->
| tradename = Abegrin
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 892553-42-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 41W9MFI160
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09342
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =
| C=6392 | H=9908 | N=1732 | O=1996 | S=42
| molecular_weight = 144.3 kg/mol
}}

'''Etaracizumab''' (also known as '''etaratuzumab'''{{Citation needed|date=September 2009}}, '''MEDI-522''', trade name '''Abegrin''') is a [[humanized monoclonal antibody]] which is being investigated for the treatment of [[metastatic]] [[melanoma]], [[prostate cancer]],<ref name="USAN" /> [[ovarian cancer]]<ref>{{cite journal|pmid=18953435|year=2008|last1=Landen|first1=CN|last2=Kim|first2=TJ|last3=Lin|first3=YG|last4=Merritt|first4=WM|last5=Kamat|first5=AA|last6=Han|first6=LY|last7=Spannuth|first7=WA|last8=Nick|first8=AM|last9=Jennnings|first9=NB|title=Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer|volume=10|issue=11|pages=1259–67|pmc=2570602|journal=Neoplasia}}</ref> and various other types of cancer.<ref>{{cite journal|pmid=17876527|year=2008|last1=Delbaldo|first1=C|last2=Raymond|first2=E|last3=Vera|first3=K|last4=Hammershaimb|first4=L|last5=Kaucic|first5=K|last6=Lozahic|first6=S|last7=Marty|first7=M|last8=Faivre|first8=S|title=Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors|volume=26|issue=1|pages=35–43|doi=10.1007/s10637-007-9077-0|journal=Investigational new drugs}}</ref> It is manufactured by [[MedImmune]].<ref name="USAN">[http://www.ama-assn.org/ama1/pub/upload/mm/365/etaracizumab.pdf Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab]</ref>
==Adverse drug effects==

{{Empty section|date=October 2014}}
==References==
{{reflist}}

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}
{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}